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Activation of the classical complement  pathway occurs when  immune  complexes 
interact with the first component, C 1, to convert it from its inactive precursor form to 
an active esterolytic enzyme, CI. 1 CI by producinglimited proteolysis of C4 and C2 
produces the classical pathway (23 convertase, C42  (1). The alternative pathway  is 
activated when  the complex surface polysaccharides of bacteria or yeasts come into 
contact with  serum  (2).  As a  consequence  of this contact,  C3b,  the major cleavage 
product of C3;  factors B  (B) 2 and D  (17)); and properdin (P)  interact to assemble the 
alternative  pathway  C3  and  C5  convertases  (3,  4).  Activation of the  complement 
system results in the generation of phlogistic molecules from C2, B, C3, and (35 which 
act on the membranes of lymphocytes, macrophages, polymorphonuclear leukocytes, 
mast cells, platelets, and smooth muscle cells (5), all of which may be involved in the 
inflammatory response. 
Modulation of complement activation is achieved by at least three plasma proteins: 
Cl-inhibitor  which  stoichiometrically inhibits  (31  (6),  C3b  inactivator  (C3BINA), 
which enzymatically inactivates C3b  (7, 8), and fllH  globulin which by binding to 
C3b, displaces Bb from the alternative pathway (33 and (35 convertases, prevents (33b 
from interacting with B  and C5, and potentiates the inactivation of C3b by C3bINA 
(9,  10). 
In  human  serum  there is usually good correlation between  concentrations  of the 
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0.086 M EDTA diluted in isotonic veronal-buffered saline containing 0.01% gelatin; D, factor E); D5W ++, 
5% dextrose containing 0.0005 M Mg  ++ and 0.00015 M Ca++; DFP, diisopropyl fluorophosphate; DGVB  ++, 
equal  volumes of D5W  ++  and veronal-buffered saline containing 0.01% gelatin,  0.0005 M  Mg  ++  and 
0.00015 M Ca++; DGVB', three volumes 5% percent dextrose and one volume isotonic veronal-buffered 
saline containing 0.01% gelatin; E  '*b, rabbit erythrocytes; 0.01 M EDTA.DGVB =, 0.086 M EDTA diluted 
in DGVB=; 0.04 M EDTA.GVB', 0.086 M EDTA diluted in isotonic veronal-buffered saline containing 
0.01% gelatin;  0.02 M  EDTA.GVB=, 0.04 M  EDTA.GVB= diluted in  isotonic veronal-buffered  saline 
containing 0.1% gelatin; 0.01 M EDTA.GVB', 0.02 M EDTA.GVB= diluted in isotonic veronal-buffered 
saline containing 0.01% gelatin; GVB  +÷, isotonic veronal-buffered saline containing 0.01% gelatin, 0.0005 
M Mg  ++, and 0.00015 M Ca++; GVB  =, GVB  ++ without Mg  ÷÷ and Ca++; MEM, Eagle's minimum essential 
medium; Mg.EGTA, one volume 0.1 M EGTA diluted in nine volumes of DGVB', containing 0.005 M 
Mg  ++, pH  7.4; P, properdin; PBS, phosphate-buffered  saline;  RD, serum  depleted of I7); RPMI.FCS, 
RPMI-1640 containing 20% heat-inactivated fetal calf serum. 
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regulatory proteins, C3bINA and fl 1H with each other and with the other components 
of the alternative pathway  (11-14).  These correlations have been used to emphasize 
the  importance  of  serum  concentrations  of  these  proteins  in  the  modulation  of 
turnover of the alternative pathway.  However, it is uncertain whether these correla- 
tions  are accounted  for by catabolic mechanisms  or whether  the synthetic rates  of 
these proteins are governed by common factors. 
In  recent  years  it  has  become  obvious  that  at  least  three  cell  types  synthesize 
complement proteins, the hepatocytes, the epithelial cells of the gastrointestinal and 
genitourinary  tracts,  and  cells  of  the  monocyte-maerophage  series  (15).  Human 
monocytes and/or  maerophages have been shown  to synthesize C 1 and  its subcom- 
ponents  (16), C4 (17,  18), C2  (18-20), and C3  (17,  18,  21). 
In  this  paper,  evidence  is  presented  to  show  that  the  human  peripheral  blood 
monocyte in short-term tissue culture synthesizes all the components of the alternative 
pathway and its control proteins and, in addition, C4, C2, and C5. 
Materials  and  Methods 
Preparation of Monocyte Monolayers.  Peripheral  blood  mononuclear  cells were  isolated  by 
centrifugation on Ficoll (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. 
J.) -Hypaque (Winthrop Laboratories, New York) cushions (22).  The cells were washed three 
times with Eagle's minimum essential medium (MEM; Gibco-Biocult Ltd., Paisley, Scotland) 
and  the cells finally resuspended in  RPMI-1640  (Gibco-Biocult Ltd.)  containing 20%  heat- 
inactivated (2 h, 56°C) fetal calf serum (RPMI.FCS) to a concentration of 1 ×  107/mi. Purified 
monocyte monolayers were prepared by layering 1 ml of cell suspensions onto a 22-mm ~quare 
glass  coverslip contained  in  a  35-  ×  10-ram  plastic  Petri  dish  (Nunc  Laboratories, Oslo, 
Norway). The Petri dishes were incubated at 37°C in a humidified atmosphere of 5% CO2 and 
air for 2 h. After incubation, the coverslips were washed vigorously with warm MEM to remove 
nonadherent  cells and  then overlayed with  2 ml  RPMI.FCS and  reincubated at  37°C  in a 
humidified 5% CO2 and air atmosphere. Using this technique, between five and seven cultures 
were prepared from each blood donation. 
All  the  cells  contained  in  monolayers  prepared  in  this  manner  stained  positively for 
nonspecific esterase (23),  and  most  phagocytosed Candida albicans. None of the cells rosetted 
with  unsensitized sheep erythrocytes (24),  but  >90%  rosetted with  EA  (7S)  (25)  and  EA43 
(19S)  (26)  showing that they possessed both Fc and C3b receptors. Using fluorescein-labeled 
anti-Ig  (Burroughs-Wellcome Ltd.,  Beckenham,  Kent,  England),  unfixed  monolayers were 
stained for surface Ig, but none of the cells showed positive staining. 
Sampling  of Cultures and Storage of Samples.  To  demonstrate  the  presence  of complement 
proteins in the culture, 200-/~1 samples of supernate were removed on days 1-9, samples from 
cultures from the same donor were pooled, and on day 12, the total supernate was harvested. 
The  removed culture  fluid was  replaced by an  equal  volume of fresh  RPMI.FCS.  In  one 
experiment, three cultures were set up and the culture medium changed daily for 10 d to study 
cumulative complement protein synthesis. 
Inhibition of Protein Synthesis.  Cycloheximide (Sigma Chemical Co., Poole, Dorset, England) 
was dissolved in RPMI.FCS to a  final concentration of 1.0 v,g/ml. Cycloheximide-containing 
control cultures were sampled on days 1, 3, and 5. On day 5, the cycloheximide-treated  cultures 
were washed and their culture medium replaced by normal RPMI.FCS, cultures were again 
sampled on day 7. 
Buffers for Functional Assays.  Isotonic veronal-buffered saline  (pH  7.4),  containing 0.01% 
gelatin, 0.0005  M  Mg  ++, and 0.00015  M  Ca  ++  (GVB÷+), 5%  dextrose containing 0.0005  M 
Mg  ++  and  0.00015  M  Ca ++  (D5W+÷),  isotonic EDTA  (0.086  M,  pH  7.4),  GVB  =  (same as 
GVB ++  but  without  Ca  ++  and  Mg++),  DGVB ++  (equal  volumes  of D5W  ++  and  GVB++), 
DGVB = (three volumes 5% dextrose without Mg  +÷ and Ca ++ and one volume GVB=), 0.04 M 
EDTA.GVB = (0.086  M  EDTA diluted in GVB=), 0.02 M EDTA.GVB = (0.04 M  EDTA,GVB = 
diluted in GVB=), 0.01  M  EDTA.GVB = (0.02  M  EDTA.GVB = diluted in GVB=), 0.01  M KEITH  WHALEY  503 
EDTA.DGVB"  (0.086  M  EDTA diluted in DGVB-; pH 6.0), Mg.EGTA (one volume 0.1  M 
EGTA diluted in nine volumes DGVB', containing 0.005 M  Mg  ÷+, pH 7.4) were used in the 
various hemolytic assays. 
Complantnt Reagents.  Human C1  (27), C2 and C4 (28),  C3 (29),  C5 (30),  B (31),  P  (32),  I) 
(33), C3hINA (34), and fllH (35) were purified and antisera to C 4, C3, C5, B, P, C3bINA, and 
flirt produced by immunization of rabbits with the purified proteins in complete Freund's 
adjuvant. Anti-C2 was a gift from Dr. Hans J. Miiller-Eberhard, Scripps Clinic and Research 
Foundation,  La Jolla,  Calif.  Functionally~ purified  C3,  C5,  C6,  C7,  C8,  and  C9  (Cordis 
Laboratories Inc., Miami, Fla.) were used in C3 and C5 hemolytic assays. Rat serum diluted 1 
to 15 in 0.04 M  EDTA.GVB"  (C-rat) was used as a source of C3-C9 in the C4, C2, B, P, D, 
C3bINA, and fllH  hemolytic assays.  Serum  depleted of I5  (RD)  was  prepared by the  gel 
filtration of fresh human  serum  over a  5.0-  X  100-cm  column  of Sephadex G75  superfine 
(Pharmacia Fine Chemicals, Inc.,  Uppsala,  Sweden).  The  exclusion peak was  rechromato- 
graphed over the same column, concentrated to the original serum volume, and was unable to 
l.,yse rabbit erythrocytes (E  tab) in Mg.EGTA (36). Lysis was restored by the addition of purified 
D, but not P  or B. E mb were separated from rabbit blood collected in Alsever's solution and 
stored at 0°C until used. EAC4 were prepared by the method of Borsos and Rapp (37). 
Functional Assays.  C2  (38),  C4  (28),  and  C3  and  C5  (39)  were  measured  by  standard 
stoichiometric hemolytic assays. 
B.  EAC43b were prepared by incubating EAC142 (1  ×  10S/ml DGVB +÷) with an equal 
volume of DGVB  ++ containing 10/tg/ml C3 at 37°C for 30 min. Conversion to EAC43b was 
achieved by incubating EAC1423b in 0.01  M  EDTA.GVB- for 2 h  at 37°C.  EAC43b were 
standardized to 1 X  10S/ml DGVB ++.  100 #l of DGVB  ++ containing I) (10 U/ml) and P  (250 
ng/ml), 50/tl of culture supernate, and  100 gl of EAC43b were mixed and incubated at 30°C 
for 30 min. 300 gti of C-rat were added to each tube, followed by a further incubation at 37°C 
for 1 h. The reaction was stopped by the addition of 2 ml 0.15 M saline, and after centrifugation, 
the degree of lysis was measured spectrophotometrically  at 4!4 nm. Controls included cell blank 
Q00/~1EAC43b + 450 gl DGVB++), reagent blank (100/~1EAC43h,  100#1DGVB ++ containing 
D and P, 50 lal RPMI.FCS, and 300/zl C-rat), 100% lysis (same as reagent blank by lysed in 2 
ml distilled water) and complement color (250 #! DGVB ++ and  300 lal C-rat). Results were 
expressed as number of hemolytic sites (Z) =  -In(1 -  y); where y =  proportion of cells lysed. 
P.  EAC43b (1 ×  10S/ml DGVB ++) prepared as described for the B assay, were incubated 
at 30°C for 30 min with an equal volume of DGVB ++ containing ID (10 U/ml) and sufficient 
B to ~roduce five hemolytic sites. The cells, EAC43b--'~'~ were centrifuged and resuspended  1 
×  10/ml in ice-cold 0.01 M EDTA.GVB-. 100/tl of EAC43bBb were incubated with an equal 
volume of supernate diluted  1 to 2 in 0.02  M  EDTA.GVB"  at  30°C  for  15  min.  After the 
addition of 0.3 ml C-rat and a further 1-h incubation at 37°C, 2 ml of 0.15 M saline was added 
to each tube to stop the reaction, and after centrifugation, the degree of lysis was measured 
spectrophotometrically at  414  nm.  Controls included cell blank (100  lal EAC43bBb,  400 gl 
DGVB++),  reagent  blank  (100  gl  EAC43b,  I00  #1  supernate  diluted  1  to  2  in  0.02  M 
EDTA.DGVB', and 300 lal C-rat), solo (100 gi EAC43bBb,  100 #1 RPMI.FCS diluted 1 to 2 
in 0.02 M  EDTA.GVB=, and 300 gl C-rat), 100% lysis (same as control, except lysed in 2 ml 
distilled water), complement color (200 gl DGVB ++, 300 #1 C-rat). The number of hemolytic 
sites per tube (Z) was calculated, and the number resulting from P activity was calculated by 
subtracting the control result from the test result. 
The kinetics of decay of C3-'b-~ in the presence of monocyte culture medium and RPMI.FCS 
was investigated. EAC43bBb  (1  ×  10S/ml 0.01  M  EDTA.GVB') prepared as described, were 
mixed with an equal volume of monocyte culture medium or RPMI.FCS diluted 1 to 2 in 0.02 
M  EDTA.GVB- at 30°C.  200-#1 samples were taken at 5,  10,  15, and 30 min, added to 300 
#1 C-rat, and incubated for a further 1 h at 37°C. After termination of the reaction, hemoglobin 
release was measured spectrophotometrically. 
fllH.  EAC43bBb, prepared as described for the P assay, were suspended to 1 ×  10a/ml in 
0.01  M  EDTA.GVB =. The convertase was stabilized by the addition of P  (250  ng/ml). The 
resultant EAC43bBbP  (100 #1) were incubated at 30°C  for  15 rain with  100 gl of supernate 
diluted  1  to  2  in  0.02  M  EDTA.GVB=.  The  residual  EAC43bBbP  hemolytic sites  were 
developed by the further incubation for 1 h in the presence of 300 #1 C-rat. The reaction was 504  COMPLEMENT  COMPONENT  AND REGULATORY  PROTEIN  SYNTHESIS 
stopped by the addition of 2 ml 0.15 M saline, and after centrifugation the degree of hemoglobin 
release  was  determined  spectrophotometrically.  Controls  included  cell  blank  (100  pl 
EAC43bBbP, 400 pl DGVB++), reagent blank (100 pl EAC43b, 100/~1 RPMI.FCS diluted 1 to 
2 in 0.02 M EDTA.GVB •,  and 300/xl C-rat), control (100 #1 EACr43bBbP,  100 #1 RPMI.FCS 
diluted 1 to 2 in 0.02 M  EDTA.GVB-, and 300 pl C-rat), 100% lysis (as for control, but lysed 
in  2 ml distilled water). The results were expressed in  Z' units, where Z' --- In of (1  -  the 
percentage of inactivation) which is: 
(the percentage of cells lysed in test sample) 
-In (the percentage of cells lysed in control [ control]) (40). 
C3blNA.  EAC43b, carrying limited C3b hemolytic sites were prepared using an R3 reagent 
as previously described (12).  100 pl EAC43b (1 ×  10S/ml 0.01 M  EDTA.DGVB', pH 6.0) were 
incubated with 50 pl culture supernate in  100 #1 0.01  M  EDTA.DGVB', pH 6.0,  for  1 h  at 
376C.  After two  washes  in  DGVB ++,  the  cells were  resuspended  in  100  #1  DGVB ++  and 
incubated with 100 #1 DGVB ++ containing B (2 ng/ml) and I) (10 U/ml) for 30 min at 30°C. 
C3bBb sites were developed by incubation with 300 pl C-rat for 1 h at 37°C. 2 ml of 0.15 M 
saline were added to stop the reaction, and after centrifugation the degree of lysis was measured 
spectrophotometrically at 414 nm. All controls were incubated with 50 #1 RPMI.FCS in  100 
/xl  0.01  M  EDTA.DGVB-  (pH  6.0)  during  the  first  incubation,  and  during  the  second 
incubation as follows: cell blank (100  #1  EAC43b,  400 #1  DGVB++),  reagent blank (100  pl 
EAC43b,  100  /~1  DGVB ++,  and  300  #1  C-rat),  control  (100  #1  EAC43b,  100  #1  DGVB ++ 
containing B [2 #g/ml] and D  [10 U/ml], and 300 #1 C-rat), 100% lysis (same as reagent blank, 
but lysed in 2 ml distilled water). Results were expressed as Z' units in the same way as the ]~IH 
results (above). 
/3.  100 pl of E ~b (1  ×  10S/ml Mg.EGTA) were incubated for 30 minutes at 30°C with 25 
pl culture supernate and 100 pl RD diluted 1 to 5 in Mg.EGTA. Excess C3-C9 was introduced 
by the addition of 300 #1 C-rat followed by a further incubation of I h at 37°C. The reaction 
was stopped by the addition of 2 ml 0.15 M saline, and after centrifugation, the degree of lysis 
rab  was measured speetrophotometrieally at 414 nm. Controls included cell blank (100 pl E  ,425 
pl  Mg.EGTA), reagent  blank  (100  pl  E tab, 25  pl  RPMI.FCS,  100  #!  RD  diluted  1 to  5  in 
Mg.EGTA, and  300  #1  C-rat),  100% lysis (as  for reagent blank, but  lysed in  2  ml  distilled 
water), complement color (25 pl RPMI.FCS, 100 pl RD,  150/d Mg.EGTA, and 300 #1 C-rat). 
Results were expressed as effective molecules of I~. In a separate experiment, monocyte culture 
fluid was incubated with 10 -3 M  diisopropyl fluorophosphate (DFP) (Sigma Chemical Co.) to 
inhibit D  activity (41). 
Radioimmunoassay for ~IH.  /~IH  (1  pg)  was  radiolabeled with  1125 (IBS3;  Radiochemical 
Centre, Amersham, Buckinghamshire, England) by the method of Hunter and Greenwood (42). 
The monomeric radiolabeled protein was separated from aggregated ~IH, and from the free 
iodide gel by filtration on an Ultrogel AcA 34 (LKB Ltd., London, England) column (1.0 ×  50 
cm). Fractions containing 12~I were tested for their ability to precipitate with anti-/31H, and the 
fractions containing immunoprecipitable protein were pooled, aliquoted, and stored at -70°C. 
Sp act of IzSI-labeled ,/~IH preparations ranged from 30 to 70 pCi/pg. 
Concentrations of,B1H  in  monocyte culture supernates were  measured  using the double 
antibody technique (43). The diluent buffer used was phosphate-buffered saline (PBS; contain- 
ing 0.01  M  phosphate, 0.3 M  NaCI,  1% bovine serum albumin, pH  7.4).  100/tl of supernate 
was incubated with  100/~1 of rabbit anti-,B1H (diluted 1 to 5,000 in PBS),  100 pg 125I-fllH  in 
100 #1 PBS, and 300 pl PBS at 4°C overnight. Antibody-bound x25I-~lH was precipitated by 
the addition of 100 pl normal rabbit serum (Burroughs-Wellcome Ltd.) diluted 1 to 25 in PBS, 
followed by a further incubation for 24 h at 0°C. Samples were centrifuged at 4°C for 30 min 
at 3,000 rpm, the supernates were removed, and the radioactivity present in the precipitate was 
measured in an automatic gamma counter  (Nuclear Chicago, High Wycombe, England). A 
standard curve was constructed by including unlabeled/~IH at concentrations ranging from 
200 ng/ml to 20 pg/ml. The assay was significantly sensitive to detect 500 pg/ml ofl~lH in the 
culture fluid. RPMI.FCS did not influence the assay. All samples were treated in duplicate, 
and duplicate samples differing by > 10% of each other were repeated. 
Incorporation of Radiolabeled Amino  Acids  into Immunoprecipitable Protein.  Radiolabeled  (4C) KEITH WHALEY  505 
valine and leucine (Radiochemical Centre) were added to RPMI.FCS to a final concentration 
of 25 /~Ci/ml. Culture fluids were harvested on day 5, pooled,  extensively  dialyzed against 
isotonic veronal-buffered saline (pH 7.4), lysophilized and redissolved in normal human serum. 
This serum was then tested by double immunodiffusion in 1.5% agarose plates, against antisera 
to C4, C3, C5, fllH, B, C3bINA, for 2 d followed by washing for 1 d in deionized water. Plates 
were air-dried, covered in plastic wrap (Perfawrap, High Wycombe, England), applied to x-ray 
film (Curix, RP1; Agfa Gevaert, Antwerp, Belgium) for 6 wk at room temperature in the dark, 
the film developed (Kodak D19, Eastman Kodak, Manchester, England) and the incorporation 
of radiolabel into immunoprecipitable protein studied. 
Immunoperoxidase Localization of Complement Protein in Monocytes.  Cultures of monocytes were 
prepared and  incubated  for 7 d  as  described above.  The culture fluid was  removed, the 
monolayers  washed  in  warm  MEM,  fixed  in  2.5% glutaraldehyde  for  30  rain  at  room 
temperature, and washed in Tris-buffered saline (0.15 M, pH 7.2). After blocking of  endogenous 
peroxidase  activity with acidified methanol containing hydrogen peroxide, monolayers were 
stained for C2, C4, C3, C5, B, P, C3bINA, or fllH by the immunoperoxidase bridge method 
(44). Negative controls were included in each run, and specificity of staining was confirmed by 
blocking experiments using purified protein preparations. Swine anti-rabbit IgG and peroxi- 
dase-anti-peroxidase  immune complexes were obtained from Burroughs-Wellcome  Ltd. 
Results 
Kinetics  of Synthesis  of Complement Proteins by  Monocytes.  Culture  supernates  were 
examined for C2, C4, C3, C5, B, D, P, C3bINA, and ,81H functional activity. C4, C3, 
and fllH were never detected, but it appeared that small quantities of functionally 
active C5 were produced in some cultures. Evidence for the production of C2, B, I), 
P,  and  C3bINA  was  obtained  by  functional  assay,  and  for fllH  production  by 
radioimmunoassay. The kinetics of production of all proteins were similar (Fig.  1), a 
slight delay in the onset of synthesis was less marked for I7) and C3bINA, followed by 
a rapid increase in synthesis between days 1 and 4, and finally, a plateau after day 5. 
On  day  6,  the  following mean  concentrations  were:  for  C2  (29  X  10  -7  effective 
molecules/culture :tz 3.2 ×  10  -7 SD), B  (133 ×  10  -7 effective molecules/culture +  37 
×  10  -7 SD), g) (85 X  10  -7 effective molecules/culture :1:7.5 x  10  -7 SD), C3blNA (45 
Z' U/culture :i:  11.6 SD), and fllH (9.8 ng/culture +  2.2 ng SD). 
In  the assays for C2, B, 17), and  P,  the number of hemolytic sites  (Z)  produced 
varied linearly with input of supernate added (Fig. 2). The volume of supernate also 
showed a linear relationship to the number of Z' units produced in the C3bINA assay 
(Fig. 2). 
Monocyte culture fluid retarded the decay ofC3bBb, the half-life of the convertase 
exposed to RPMI.FCS was 4 min and that exposed to monocyte culture fluid was 8 
min (Fig. 3). 17) activity in monocyte culture fluid was completely inhibited by 10  -8 M 
DFP. 
Cumulative Synthesis of Complement Proteins.  In three cultures set up in duplicate, the 
culture medium was Changed daily (Fig. 4). The quantities of C2, B, I7), P, C3bINA, 
and fllH synthesized per day were added, and it was found that after day 1, synthesis 
continued at a constant rate up to day 10 without a plateau being reached. The slight 
flattening of the curve between days 9 and  10 probably reflects death of cells in the 
cultures. The slopes of the six graphs are very similar. 
Cyctoheximide-induced Inhibition of Synthesis.  Incorporation of cycloheximide (1.0/~g/ 
ml) into the culture medium produced inhibition of C2, B, I~, P, C3bINA, and fllH 
synthesis  (Fig.  5).  When  the  cyeloheximide-containing medium  was  removed the 506  COMPLEMENT COMPONENT AND REGULATORY PROTEIN SYNTHESIS 
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FIG.  1.  Kinetics  of synthesis of C2, B, D, P, G3blNA, and fllH. Concentrations of C2, B, 13, and 
P are expressed as effective molecules (Eft. mols) (X 10  -7) per culture; C3blNA concentrations are 
expressed as Z' units per culture  (Materials and Methods); ,81H concentrations are expressed as 
nanograms of/~lH per culture. The results are the mean (0) 4- SD (O) of six cultures. 
monolayers washed in RPMI and recultured in fresh RPMI.FCS on day .5, synthesis 
of all six proteins were detected. 
Incorporation of t+C-labeled Amino Acids into Immunoprecipitable Protein.  As can be seen 
in Fig. 6, a4C-labeled amino acids were incorporated into G4, C3, C5, t~, P, C3bINA, 
and/31H.  Culture fluids containing cyeloheximide (1.0/~g/ml)  failed to show incor- 
poration of 14C-labeled amino acids into protein. 
Immunoperoxidase Localization of Complement Proteins.  All  the  monoeytes  in  each 
culture stained for C4, C2, C3, C5, B, P, G3bINA, and ~IH  (Fig. 7). Virtually all the 
cells in each culture stained  positively for all the proteins studied.  The cytoplasm of 
monoeytes which had retained their rounded shape throughout the period of culture 
stained  densely,  whereas  monocytes  which  had  spread  showed  a  dense  granular KEITH WHALEY  507 
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Fxo. 2.  Titration of supernates for C2, B, l~, P, and C3bINA. The number of effective molecules 
(Z) of C2, B, I), and P, and the number of Z' units (Materials and Methods) of C3bINA are plotted 
on the ordinates, and the input of supernate on the abscissas. 
perinuclear stain  associated with  fine granular  cytoplasmic staining.  Staining with 
each antigen was blocked by prior absorption with the purified antigen; replacing the 
antiserum by nonimmune serum resulted in background staining only. 
Discussion 
The  evidence  that  the  cultured  cells  stained  positively  for  nonspecific  esterase, 508  COMPLEMENT COMPONENT AND  REGULATORY PROTEIN SYNTHESIS 
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Fie.  3.  Kinetics  of decay of EAC43bBb in fresh RPMI.FCS (control) (×) and in monocyte culture 
fluid (O) at 30°C, The number of hemolytic sites (Z)  (Materials and Methods) is plotted on the 
ordinate and time (in minutes) on the abscissa. The monocyte culture fluid slows the rate of decay 
of EAC43bBb (tx/2 -- 8.0 min vs. 4.0 rain for RPMI.FCS [control]). 
possessed  Fc  and  C3b  receptors,  and  phagocytosed  C.  albicans, coupled  with  the 
observations  that  they lacked sheep  erythrocyte receptors  and  surface  Ig, and  their 
morphological  appearances  all  suggested  that  the  cells  were  monocytes  free  from 
lymphocytes and polymorphonuclear leukocyte contamination. 
Previous studies (18-20)  have shown that human monocytes in culture are capable 
of synthesizing  C2,  an  observation  we  have  used  in  these  experiments  to  test  the 
ability of our cultures  to synthesize a  complement  protein,  which also verifies these 
previous reports. 
Evidence  has  been  provided  (Table  I,  summary_)  that  monocytes in  addition  to 
synthesizing  C2,  also  synthesize  C4,  C3,  C5,  B,  D,  P,  C3bINA,  and  fllH.  Using 
functional assays, B, D, P, and C3bINA activity were found (Fig.  1) whereas C4, C3, 
and  fllH  activities  could  not  be  detected,  although  the  assays  used  would  detect 
200,000  effective molecules of C4 and  40,000 effective molecules  of C3  per  ml of a '/5 
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Ftc. 4.  Cumulative  synthesis of C2, B, l), P, C3blNA, and fllH by monocytes.  Culture fluid was 
replaced with fresh RPMI.FCS daily and the number of effective molecules (Z) (Materials and 
Methods) of C2, B, I), and P, Z' units of  C3bINA and nanograms offllH synthesized  each day were 
added together (shown on the ordinate). No plateau was seen after day 5. The results are the mean 
(0) and range of ((3) of three cultures. 
standard pool of human serum, and  20 ng/ml of fllH.  However, using a  radioim- 
munoassay, increasing concentrations of fllH were found in the culture supernates 
(Fig.  1).  In  addition  to  the  functional  assays  described,  P  activity was  capable  of 
stabilizing C3bBb  (Fig. 3) and I~ activity inhibited by DFP (10  -a M). Incorporation 
of cycloheximide (1.0 ~g/ml) into the culture medium resulted in reversible inhibition 510  COMPLEMENT  COMPONENT  AND REGULATORY PROTEIN  SYNTHESIS 
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The reversible  nature of cycloheximide-induced inhibition of C2, B, 15, P, C3blNA, and 
fllH synthesis. Monocytes were incubated in RPMI.FCS (0) or RPMI.FCS containing cyclohexi- 
mide 1.0 #g/ml (O). On day 5, the cycloheximide-containing cultures were washed with RPMI and 
fresh RPMI.FCS was added. By day 7, synthesis of all proteins  was restored.  Results  for C2, B, I~, 
and P (effective molecules  [×  10-7]/culture),  C3bINA (Z' units  [Materials and Methods]/culture) 
and BIH (nanograms/culture)  are shown  on the ordinates, and incubation time (days) shown on 
the abscissas. 
of C2, B, 15, P, C3bINA, and fllH synthesis (Fig.  5).  14C-labeled amino acids were 
incorporated  into  C4,  C3,  C5,  B,  P,  C3bINA,  and  /~IH  protein  (Fig.  5),  but 
incorporation into l~ could not be tested for because of lack of suitable antiserum. 
Finally, using the immunoperoxidase technique, C2, C4, C3, C5, B, P, C3bINA, 
and  /~IH  were  found  in  all  the  cultured  cells  (Fig.  7)  which  is  in  agreement  with 
findings  of  Einstein  et  al.  (18)  who  found  lysozyme  was  present  in  all  human 
monocytes  in  culture.  This  may  not  mean  that  all  monocytes are synthesizing  these 
proteins;  it  is equally possible  that  only subpopulations  have  this  property  and  the KEITH WHALEY  511 
Flo. 6.  Incorporation of 14C-labeled amino acids into immunoprecipitable protein, (1) The con- 
centrated monocyte culture fluid is in the center well and antisera are in the peripheral wells: a, 
anti-C4; b, anti-C3; c, anti-flirt;  d, anti-B; and e, anti-C5. (2) The concentrated monocyte  culture 
fluid is in well a, and anti-P in well b. (3) The concentrated monocyte  culture fluid is in well a, and 
anti-C3blNA is in well b. 
remainder pinocytose, or adsorb onto their surfaces, the newly synthesized proteins. 
Ultrastructural localization studies will discriminate among these possibilities. 
From  the  failure to  detect  functionally active C4,  C3,  or ~IH  and  the  irregular 
detection of C5 activity, it could be argued that  the detection of ~4C-labeled amino 
acids in the immunoprecipitable proteins could represent nonspecific binding to the 
carrier proteins (15).  However, the immunoperoxidase localization studies, the cyclo- 
heximide-induced  inhibition  of X4C-labeled  amino  acids  into  immunoprecipitable 
protein,  and  the  detection  of fllH  by  radioimmunoassay,  all  argue  against  this 
possibility. Three other explanations are possible: (a) monocytes synthesize and secrete 
precursor molecules which require proteolytic cleavage to be converted to the active 
molecule  (45),  (b)  molecules are  synthesized  in  active  form, but  are enzymatically 
degraded in the culture fluid, and  (c)  their concentrations may be too low to permit 
detection in the functional assays employed. C4 is apparently synthesized by mono- 
cytes  as  the single  polypeptide  chain,  pro-C4,  whereas  C3  is  present  as  a  double 
polypeptide chain, and therefore has presumably been degraded in the culture fluid 
after synthesis (H. R. Colten.  Personal communication.). The explanation why ~OlH 
was not detected functionally in the assay described here, could be a  result of the low 
concentrations  of the  protein  found  (5  ng/ml)  in  the  culture  fluids  (Fig.  1).  In 
experiments investigating the  mechanism of destabilization  of C3bBbP  by/~IH, it FIo.  7.  Immunoperoxidase localization  of complement proteins.  (A)  Anti-~81H. The  rounded 
monocytes  show  an  extremely dense granular  staining, whereas the monocytes with  spreading 
cytoplasm show dense perinuclear granules with fine granular cytoplasmic staining. × 400. (B) Anti- 
~81H absorbed with purified ~81H. The staining pattern, shown above is completely inhibited. X 
400. 
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TABLE I 
Summary of Procedures Used  to Detect Components Studied 
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C2  (34  C3  C5  B  l)  P  C3bINA  fllH 
Functional assay  +  -  -  fl=  +  +  +  +  - 
Radioimmunoassay  ND  ND  ND  ND  ND  ND  ND  ND  + 
Cycloheximide inhibi-  +  +  +  +  +  +  +  +  + 
tion 
Incorporation of  ND  +  +  +  +  ND  +  +  + 
14C-amino acids 
ND, not done. 
was difficult to detect concentrations of fllH <20 ng/ml  (10, 35).  It is also possible 
that  fllH  is  secreted  into  the  culture  fluid  as  an  inactive  pro-fllH  molecule:  this 
possibility is currently under investigation. 
The detection  of hemolytically active B  in  these experiments is  at  variance with 
results obtained using guinea pig macrophage culture supernates, in which all the B 
is inactivated after its synthesis in the presence of functionally active D  and C3, (46). 
The inactivation  process  probably depended  upon  cleavage of B  by I) during  the 
assembly of the alternative pathway C3 convertase in the culture fluid. The ability to 
detect  hemolytically active C3  in guinea pig macrophage cultures  must be because 
the amount of C3bBb  formed in the culture fluid is limited by the availability of B, 
when D  and (23 are in excess. In contrast, in the human monocyte system described 
here, the limiting factor must be C3 as B and D are detected: either insufficient (]3 is 
synthesized to turnover all the B produced, or the C3 is incapable of participating in 
the formation of a (23 convertase because it is in the form of an inactive precursor, or 
has been somehow degraded after synthesis. 
It has previously been shown that proteolytic enzymes can substitute for I) in the 
formation of C3bBb  (47)  and therefore, in the absence of immunoperoxidase locali- 
zation  with  specific  anti-I)  antibody,  it  is  possible  that  other  monocyte-derived 
enzymes could be responsible for the D-like activity measured. Likewise, it is conceiv- 
able that certain lysozomal hydrolases could inactivate C3b;  and thus the C3bINA 
activity observed could be a result of a combination of the actions of C3bINA and/or 
other enzymes. Molecular characterization of D  and C3bINA activities in monocyte 
culture fluid should resolve these problems. 
The recent  observations that  human  peritoneal  macrophages synthesize hemoly- 
tically active C~ and its three subcomponents (16), together with the data presented 
in this communication, demonstrate that cells of the human monocyte-macrophage 
series  are  capable of synthesizing  all  the  components which  should  ultimately  be 
capable of forming the C3 and C5 convertases of both the classical and alternative 
pathways. Macrophages from laboratory animals are also capable of synthesizing the 
components of the classical and alternative pathways (15,  16,  46,  48)  but  have not 
been shown to produce C3bINA or flirt. By synthesizing C5, they produce the three 
proteins, C3, C5, and B, which  are currently thought  to provide most of the major 
phlogistic cleavage products of complement' activity. The mobile nature of this source 
of complement components could have important consequences on the development 
of the local inflammatory reaction. The synthesis of the regulatory proteins C3bINA 
and fllH may be important  in modulating the extent  of complement activation at 
such sites. 514  COMPLEMENT COMPONENT AND REGULATORY PROTEIN  SYNTHESIS 
The similarity of the observed rates of synthesis of C2, B, [), P, C3bINA, and fll H 
(Fig.  2)  suggest that action of a  common controlling factor or factors, which  could 
account for the correlation between the serum levels of these proteins. 
Summary 
Short-term cultures of human peripheral blood monocytes were shown to synthesize 
the alternative pathway complement components C3, factors B  (B)  and I) (D), and 
properdin,  the regulatory proteins (23b inactivator  (C3bINA) and fllH, in addition 
to C2, C4, and C5.  B, l), properdin,  C3bINA, and C2 were detected by functional 
assays, whereas fllH, C4, C3, and t25 could only be detected using immunochemical 
procedures. Immunoperoxidase localization studies showed that all the cells in each 
culture contained each component, so it is possible that all monocytes synthesize each 
component. 
It is concluded that cells of the monocyte-macrophage series form a  mobile source 
of complement components and  regulatory  proteins which  can be concentrated  at 
sites of inflammation. 
The excellent  technical assistance  of Mrs. S. Lennie and Mr. W. Smith is gratefully acknowl- 
edged. 
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